Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable January 30, 2026, to shareholders of record at the close of business on December 31, 2025, representing an increase of 4.8% versus the prior year and previous quarter. “We remain confident in our ability to deliver strong financial performance, and consistent with our capital allocation priorities we are increasing our dividend to $0.88 p ...

Core Viewpoint - Teleflex Incorporated has announced the sale of its Acute Care, Interventional Urology, and OEM businesses for a total of $2.03 billion in cash, which will enhance its focus on core medical technology markets and allow for significant capital return to shareholders through a new $1 billion share repurchase program [1][2][4][6]. Group 1: Transaction Details - The transactions involve the sale of the OEM business for approximately $1.5 billion and the Acute Care and Interventional Urology businesses for $530 million, with net proceeds expected to be around $1.8 billion after tax [4]. - The completion of these transactions is anticipated in the second half of 2026, pending regulatory approvals and other customary closing conditions [3]. Group 2: Strategic Focus - The company aims to optimize its portfolio and position itself as a leader in critical care and high acuity hospital markets, focusing on Vascular Access, Interventional, and Surgical businesses [2]. - Following the transactions, Teleflex expects to achieve mid-single-digit growth and enhance operational efficiency, which will drive value for shareholders and improve service delivery to customers and patients [2]. Group 3: Share Repurchase Program - The Board of Directors has authorized a share repurchase program of up to $1 billion, primarily funded by the proceeds from the recent sales [6]. - The repurchase strategy will be flexible, depending on market conditions and other factors, and may include various methods such as open market transactions and privately negotiated deals [7]. Group 4: Advisory Support - Centerview Partners LLC is acting as the financial advisor, while Simpson Thacher & Bartlett LLP serves as legal counsel, and Joele Frank provides strategic communications support to Teleflex [8].

U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday.Shares of Meihua International Medical Technologies Co., Ltd. (NASDAQ:MHUA) fell sharply in pre-market trading after the company announced that it will be delisted from the Nasdaq.Meihua International Medical Technologies shares dipped 32.9% to $9.41 in pre-market trading.Here are some other stocks moving lower in pre-market trading.SMX (Security Matters) Public Limited Company (NASDAQ:SMX) shares dipped 17.2% to ...

Dylan Crotty promoted to Group President, OrthopaedicsPortage, Michighan, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today Spencer Stiles has been appointed President and Chief Operating Officer (COO), effective January 1, 2026. In this role, Stiles will lead the company’s global businesses, strategy, and mergers and acquisitions. “Appointing Spencer President and COO strengthens our ability to sustain high growth and leverage the breadth of our ...

CEO's personal open-market investment reflects long-term alignment with shareholders and continued commitment to transparency, excellence and innovation. MESA, ARIZONA / ACCESS Newswire / November 20, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE) (the "Company") today announced that its Chief Executive Officer, Marshall Perkins, purchased 50,000,000 shares of MDCE common stock on the open market at an average purchase price of $0.0003 per share on November 19, 2025. ...

Core Points - Covalon Technologies Ltd. announced its first-ever special cash dividend of C$0.15 per common share, to be paid on November 18, 2025, indicating strong financial performance [1] Financial Performance - The declaration of the special dividend reflects the company's continued success in accelerating the adoption of its unique, patented medical technologies [1]

Group 1 - Teleflex Incorporated will present at the Jefferies Global Healthcare Conference in London on November 18, 2025, at 10:00 a.m. GMT [1] - A live audio webcast of the presentation will be accessible on the investor section of the Teleflex website [1] Group 2 - Teleflex is a global provider of medical technologies focused on improving health and quality of life [2] - The company aims to be the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, radiology, surgical, vascular access, and urology [2] - Teleflex believes in the potential of people, purpose-driven innovation, and world-class products to shape the future of healthcare [2] Group 3 - Teleflex is home to several trusted brands including Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüsch™, UroLift™, and Weck™, all united by a common purpose [3] - The company emphasizes its commitment to empowering the future of healthcare [3]

Core Points - Teleflex Incorporated will host a conference call on November 6, 2025, at 8:00 a.m. Eastern Time to discuss its third quarter financial results and provide an operational update [1] - An audio replay of the call will be available starting at 11:00 a.m. Eastern Time on the same day [2] - A virtual meeting regarding the recent Vascular Intervention business acquisition will take place on November 14, 2025, at 8:00 a.m. Eastern Time [3] Company Overview - Teleflex is a global provider of medical technologies focused on improving health and quality of life [4] - The company aims to be the most trusted partner in healthcare, offering a diverse portfolio in various therapy areas including anesthesia, emergency medicine, interventional cardiology, and more [4] - Teleflex is associated with several trusted brands such as Arrow™, Barrigel™, and UroLift™, which are united by a common purpose [5]

Core Insights - Johnson & Johnson (NYSE: JNJ) is undergoing significant restructuring, including a second major spin-off of its orthopedics division, which is expected to be completed within 18 to 24 months [2][4] - The company anticipates revenue growth exceeding 5% in 2024, surpassing analysts' expectations of 4.6%, and projects adjusted earnings to exceed Wall Street's estimate of $11.39 per share by up to 5 cents [3] - Johnson & Johnson has maintained a strong dividend tradition, raising its payouts for 63 consecutive years, with a current quarterly dividend of $1.30 per share and a dividend yield of 2.74% as of October 14 [6] Company Developments - The orthopedics division, which generated approximately $9.2 billion in revenue last year, accounts for about 10% of the company's total sales [4] - The new company formed from the spin-off will be named DePuy Synthes and will be led by industry veteran Namal Nawana [4] - In 2023, Johnson & Johnson initiated a two-year restructuring plan for its orthopedics unit, which includes market exits and product discontinuations, following the spin-off of its $15 billion consumer health business into Kenvue [5]

Group 1 - Johnson & Johnson is focusing on innovative cancer drugs and medical devices, particularly in cardiovascular care, as highlighted by CEO Joaquin Duato [1][2] - The company is currently facing talc lawsuits, but there is a belief that the risk from asbestos and baby powder litigation has peaked, with J&J winning several cases [1] - J&J plans to continue fighting the lawsuits individually, with expectations that plaintiffs may eventually find it too costly to pursue [1] Group 2 - Johnson & Johnson develops a wide range of pharmaceuticals and medical technologies, including areas such as immunology, oncology, and cardiovascular care [2]